F-1/A: Lytus Technologies Seeks Nasdaq Listing Amidst Public Offering

Lytus Technologies Holdings PTV. Ltd. files an F-1/A to offer 1 million common shares, aiming for a Nasdaq listing and capital raise, despite recent delisting from Nasdaq and internal control challenges.

Summary

• Lytus Technologies Holdings PTV. Ltd. is offering 1,000,000 common shares in a firm commitment underwritten public offering, with an expected price range of $5.00 to $7.00 per share.
• The company has applied to list its common shares on the Nasdaq Capital Market under the symbol LYT, with the closing of the offering contingent upon this approval.
• Lytus's common shares are currently quoted on the OTCID under the symbol LYTHF, with a last reported sale price of $13.25 per share on December 29, 2025.
• A 1-for-2,500 reverse stock split became effective on September 26, 2025, impacting the number of outstanding shares.
• Net proceeds from the offering are estimated at approximately $4.7 million, with $1.6 million allocated to repay a promissory note to Yorkville and $3.1 million for working capital and general corporate purposes.
• For the fiscal year ended March 31, 2025, total revenue increased by 0.80% to $23,186,534, while net income after tax increased by 27% to $829,412.
• Basic earnings per common share for FY2025 was $0.12, compared to $0.30 for FY2024.
• The company reported material weaknesses in internal control over financial reporting and ineffective disclosure controls and procedures as of March 31, 2025.
• Dharmesh Pandya, CEO, and the Lytus Trust collectively hold approximately 78% of voting stock, which will be approximately 52% post-offering, making Lytus a controlled company under Nasdaq rules.
• The company operates primarily in India, offering streaming/telecasting services and developing healthtech and fintech products, with plans for expansion into the U.S. for telemedicine and streaming.
• Subsequent to March 31, 2025, the company increased its authorized share capital to 5,000,000,000 shares and issued 3,800,000,000 restricted common shares to the Lytus Trust for future employee allocation.
• Additionally, 965,000,000 common shares were sold to two investors in a private placement for $15,440,000 on July 7, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the recent Nasdaq delisting, identified material weaknesses in internal controls, and the significant disparity between the OTC trading price and the proposed public offering price, which suggests a distressed capital raise. While there is revenue growth and strategic expansion, these negatives overshadow the positives and indicate substantial risks for investors.

Positives

• Total revenue increased by 0.80% to $23,186,534 for the fiscal year ended March 31, 2025, compared to $23,003,342 in the prior year.
• Operating revenue from customer contracts increased by 8.26% to $23,127,919 for FY2025, driven by growth in carriage and placement fees and new consultancy services.
• Net income after tax increased by 27% to $829,412 for FY2025, up from $653,174 in FY2024.
• Net cash provided by operating activities significantly increased to $2,164,425 for FY2025, compared to $886,034 in FY2024.
• The company has a strong customer base of 1 million paid home subscribers, translating to an estimated 4 million active users in India, with subscriber growth of approximately 14.67% from March 31, 2024, to March 31, 2025.
• Strategic expansion into healthtech and fintech services is underway, leveraging existing infrastructure and market presence in India.
• The company believes it has sufficient short-term and long-term liquidity from cash on hand, free cash flow, and access to capital markets to fund projected cash needs.
• Capital advances for property, plant, and equipment, including $8.4 million for Audio OTT, IPTV platform, and IPTV box development, indicate ongoing investment in technology and infrastructure.

Negatives

• The company received notice of delisting from Nasdaq on March 27, 2025, and trading was suspended on March 31, 2025, with Nasdaq filing to withdraw registration on July 21, 2025.
• Other income decreased significantly by 96.42% to $58,615 for FY2025, primarily due to a one-time write-off of warrant liability in the prior fiscal year.
• Basic earnings per common share decreased to $0.12 for FY2025 from $0.30 for FY2024, despite an increase in net income, indicating significant share dilution.
• The proposed public offering price range of $5.00-$7.00 per share is substantially lower than the last reported OTCID sale price of $13.25 per share on December 29, 2025, suggesting a significant valuation discount.
• The company identified material weaknesses in its internal control over financial reporting and determined its disclosure controls and procedures were ineffective as of March 31, 2025.
• The CEO, Dharmesh Pandya, is involved in a legal proceeding filed May 22, 2020, alleging breach of contract and fiduciary duty with claimed damages of $854,000.
• The company's status as a foreign private issuer and controlled company allows it to rely on exemptions from certain Nasdaq corporate governance requirements, potentially affording less protection to shareholders.

Risks

• Uncertainty regarding the development or sustainability of an active public trading market for common shares, especially after Nasdaq delisting.
• The common shares are currently quoted on the OTCID, which may unfavorably impact stock price and liquidity, and there is no assurance of Nasdaq listing approval.
• Inability to satisfy ongoing listing requirements of Nasdaq or any other national securities exchange, leading to potential delisting.
• U.S. broker-dealers may be discouraged from effecting transactions in common shares if they are considered 'penny stock' (under $5.00), reducing liquidity.
• Substantial future sales of common shares or the perception of such sales may depress the stock price and cause dilution.
• Broad discretion in the use of net proceeds from the public offering, which may not yield a favorable return on investment.
• Volatility of the common share price due to various factors beyond the company's control, including technological innovations, personnel changes, and economic factors.
• The company does not plan to pay dividends in the foreseeable future.
• Disclosure obligations as a foreign private issuer differ from U.S. domestic reporting companies, potentially making it harder for investors to evaluate performance.
• Being a controlled company allows reliance on exemptions from certain Nasdaq corporate governance standards, potentially affording less protection to shareholders.
• Raising additional capital may adversely affect shareholder rights, restrict operations, or require relinquishing rights to technologies.
• Lack of research coverage by industry or securities analysts could cause stock price and trading volume to decline.
• Limited operating history and rapid growth make evaluating current business and future prospects difficult and increase investment risk.
• Revenues and expenses are difficult to predict due to the nature of the markets, increasing the likelihood of results falling below expectations.
• Risks related to the storage of customer confidential information and cybersecurity incidents, which could harm business and expose to liability.
• Significant expense may be incurred to further develop the platform, which may not become sufficiently successful.
• Inability to obtain or protect intellectual property rights could harm the brand and business.
• High dependence on clients in India and concentration in IT, healthcare, and streaming industries make the business vulnerable to economic slowdowns or industry-specific factors.
• Potential liability risks inherent to the healthcare industry, with expensive and difficult-to-obtain insurance.
• The telehealth market is immature and volatile; slow development, negative publicity, or lack of competitiveness could harm business growth.
• Legal challenges to the business model or actions restricting the ability to provide services in certain jurisdictions could adversely affect operations.
• Difficulties in managing growth due to the need to increase organization size and recruit/retain new employees.
• Material weaknesses in internal control over financial reporting and ineffective disclosure controls and procedures could lead to inaccurate financial reporting.
• Reliance on key existing and future personnel, with the loss of key individuals like CEO Dharmesh Pandya having a material adverse effect.
• Reliance on information technology; failure to adapt to technological developments or industry trends could harm the business.
• Operation in highly competitive industries, facing competition from entities with superior resources or competitive advantages.
• Dependence on the ability to recruit and retain experienced therapists for the healthcare segment.
• Healthcare provider licensing and credentialing costs can negatively impact margins, especially when expanding to new jurisdictions.
• Reliance on third-party systems and service providers; disruptions or adverse changes could materially affect the business.
• Failure to maintain or enhance consumer awareness of the brand could have a material adverse effect.
• Inability to successfully implement growth strategies, including expanding service portfolios, investing in technology, and pursuing strategic partnerships/acquisitions.
• Inability to continue identifying and exploiting new market opportunities could lead to declining future revenues.
• Difficult market conditions, economic conditions, and geopolitical uncertainties could adversely affect business and financial performance.
• Changing laws, rules, and regulations, including adverse application of tax laws, may adversely affect business and financial performance.
• Infrastructure in India may not be upgraded to support higher internet penetration, requiring additional investments and expenses.
• Results of operations are subject to fluctuations in currency exchange rates.
• Inability to obtain additional financing on acceptable terms, if needed, could prevent business development or response to competitive pressure.
• Exposure to intellectual property infringement claims, which may be expensive to defend and disrupt business.
• Reliance on highly technical software that may contain undetected errors, adversely affecting business.
• Substantial portion of business and operations in India subjects the company to regulatory, economic, social, and political uncertainties in India.
• Restrictions on foreign investment in India may prevent future acquisitions or investments.
• Business and activities are regulated by The Competition Act, 2002, with potential for substantial penalties.
• The healthcare industry in India is subject to extensive laws, rules, and regulations, with non-compliance leading to regulatory action and penalties.

Future Outlook

The company plans to expand its service and product portfolio, enhance its technology platform with AI and ML, and enter new geographic markets, particularly in healthtech and fintech. It intends to fund these initiatives through operational cash flow, customer deposits, credit lines, and future securities offerings. The telemedicine business is expected to launch subscription-based remote patient monitoring devices in India and the U.S. in the second half of 2025, with local health centers rolling out over 24 months. Fintech services will initially target existing cable customers for e-wallet payments, with plans to offer credit cards and microloans. The company also aims to produce original content through Lytus Studios.

Management Comments

• Management believes that increasing the subscriber base will enable continuous innovation and enhance subscriber experiences, leading to increasing or maintaining the existing annual net dollar retention rate.
• Management believes that the deep understanding and local expertise of the Sri Sai and Lytus Health teams will help create a profitable and sustainable business model with rapid growth prospects.
• Management believes that the proceeds from this offering will be sufficient to satisfy the company's cash needs for the next 12 months.
• Management will monitor the effectiveness of remediation plans for internal control weaknesses and make appropriate changes.

Industry Context

The company operates within the rapidly evolving Indian streaming, internet, healthtech, and fintech sectors. It aims to capitalize on India's e-commerce boom, increasing internet penetration, and the recent telemedicine regulatory regime. The IPTV market in India is expected to grow due to video-on-demand popularity, smartphone penetration, lower data tariffs, rapid urbanization, and government digital transformation initiatives. The company faces competition from established players like JioHotstar, Netflix, Practo, 1mg, Apollo 24/7, Amazon Pay, Ola Money, and JioMoney in its various segments.

Management Changes

Corporate Governance

Legal Proceedings

• Dharmesh Pandya, the Chief Executive Officer, is a defendant in a lawsuit filed on May 22, 2020, in Florida, alleging breach of contract and breach of fiduciary duty, with claimed damages of $854,000. The company believes the claims are false and frivolous, and Mr. Pandya is actively defending them.

Related Party Transactions

• Subscription income from related parties: $518,795 for FY2025.
• STB Installation charges from related parties: $48,445 for FY2025.
• Loans taken from KMP: $272,365 for FY2025.
• Loan repayment to KMP: $1,543,653 for FY2025.
• Commission expenses to significant influence entities: $1,305,186 for FY2025.
• Consultancy services revenue from significant influence entities: $1,061,622 for FY2025.
• Remuneration to KMP: $141,797 for FY2025 (deferred and unpaid).
• Remuneration to relatives of KMP: $38,286 for FY2025.
• Investment in Compulsory Convertible Debentures of Subsidiary: $3,817,490 for FY2025.
• Outstanding loan payable to KMP: $164,124 as of March 31, 2025.
• Outstanding loan payable to related party: $31,019 as of March 31, 2024 (zero in 2025).

Stakeholder Impact

• Existing shareholders will experience immediate and substantial dilution in net tangible book value per share ($4.51 dilution) due to the public offering at a price significantly below current book value.
• New investors in the public offering will acquire shares at a lower price ($5.00-$7.00) compared to the last OTCID trading price ($13.25), potentially benefiting from a discounted entry point.
• Employees may benefit from future allocations of 3,800,000,000 restricted common shares from the Lytus Trust under the 2023 Employee Incentive Plan, though no awards have been granted yet.
• Creditors, particularly Yorkville, will see a $1.6 million repayment of a promissory note from the offering proceeds, reducing the company's debt obligations.
• Customers in India are expected to benefit from enhanced streaming, healthtech, and fintech services as the company invests in technology upgrades and expands its service portfolio.
• The Nasdaq delisting and material weaknesses in internal controls could negatively impact investor confidence and the company's ability to access capital markets in the future.

Next Steps

• Obtain approval for listing common shares on the Nasdaq Capital Market.
• Consummate the public offering of 1,000,000 common shares.
• Repay the outstanding $1.6 million promissory note to Yorkville.
• Utilize $3.1 million for working capital and general corporate purposes, including potential strategic transactions.
• Continue development and launch of subscription-based remote patient monitoring devices in India and the U.S. in the second half of 2025.
• Proceed with the 24-month rollout plan for local health centers and diagnostic centers in India.
• Expand Fintech services, starting with e-wallet payments and later offering credit cards and microloans.
• Produce original content through Lytus Studios.
• Monitor and remediate identified material weaknesses in internal control over financial reporting and improve disclosure controls and procedures.
• Address the ongoing legal proceeding involving the CEO, Dharmesh Pandya.

Key Dates

Recommendation

The company faces severe headwinds, including a recent delisting from Nasdaq, which is a major blow to its public market credibility and liquidity. The proposed public offering price of $5.00-$7.00 is a substantial discount to its current OTCID trading price of $13.25, indicating a significant perceived devaluation by the market or a distressed capital raise. Furthermore, the company has acknowledged material weaknesses in its internal control over financial reporting and ineffective disclosure controls, which are critical governance failures. The significant dilution for existing shareholders, coupled with the CEO's ongoing legal proceedings and the company's status as a controlled foreign private issuer with reduced governance requirements, presents a high-risk investment profile. While there is some revenue growth and strategic expansion, the fundamental issues of delisting, valuation disparity, and internal control deficiencies make this a highly speculative and unfavorable investment.

Keywords

Streaming, IPTV, Telemedicine, Fintech, India, Nasdaq, Public Offering, SEC Filing, Lytus, Reverse Stock Split, Corporate Governance, Risk Factors, Financial Results